Across TCGA pan-cancer cohorts, SMIM27 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SMIM27 data layer compared with 19 for mass-spec protein.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher SMIM27 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SMIM27 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.
GBM are the cancer types where SMIM27 mass-spec protein most reproducibly stratifies survival.